Get the Stockscreener App
15.11
0.20%
-0.03
Intellia Therapeutics Inc stock is traded at $15.11, with a volume of 911.66K.
It is down -0.20% in the last 24 hours and down -16.01% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$15.14
Open:
$14.76
24h Volume:
911.66K
Relative Volume:
0.52
Market Cap:
$1.54B
Revenue:
$52.60M
Net Income/Loss:
$-485.50M
P/E Ratio:
-2.7674
EPS:
-5.46
Net Cash Flow:
$-418.08M
1W Performance:
+0.80%
1M Performance:
-16.01%
6M Performance:
-35.97%
1Y Performance:
-47.46%
1-Day Range:
$14.55
$15.26
1-Week Range:
$13.95
$15.30
52-Week Range:
$13.95
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Data UnderwhelmsIntellia's Cash, Data And Competition Are A Challenging Story - Seeking Alpha
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - Yahoo Finance
(NTLA) Long Term Investment Analysis - Stock Traders Daily
Capital Advisors Inc. OK Has $4.19 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
NTLAIntellia Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - GlobeNewswire
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study - MSN
Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies - Insider Monkey
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
In the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Reasons For Intellia Therapeutics Stock Plunge Are Flimsy, But Don't Buck Mr. Market - Seeking Alpha
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 5.8%What's Next? - MarketBeat
Oversold Conditions For Intellia Therapeutics (NTLA) - Nasdaq
Intellia Therapeutics Advances with Promising Phase 2 Results - Yahoo Finance
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy - MSN
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity (NTLA) - Seeking Alpha
Intellia Therapeutics price target lowered to $65 from $80 at BofA - MSN
Intellia reports positive data from Phase II study of NTLA-2002 for HAE - Clinical Trials Arena
7 Analysts Have This To Say About Intellia Therapeutics - Benzinga
Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study - BioSpace
Robert W. Baird Trims Intellia Therapeutics (NASDAQ:NTLA) Target Price to $18.00 - MarketBeat
Phase II Intellia data fail to impress investors - The Pharma Letter
Intellia trumpets CRISPR drug data, but shares fall - pharmaphorum
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Intellia's CRISPR drug slashes HAE attacks, but investor doubts persist - FirstWord Pharma
Why Intellia Therapeutics Stock Plummeted by 20% Today - sharewise
Why Intellia Therapeutics (NTLA) Stock Dropped Today - GuruFocus.com
Intellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan Capital - MarketBeat
A Closer Look at Intellia Therapeutics's Options Market Dynamics - Benzinga
Intellia stock touches 52-week low at $16.86 amid market shifts By Investing.com - Investing.com South Africa
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? - Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release - Yahoo Finance
Intellia retains outperform stock rating amid trial results - Investing.com
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Fo - GuruFocus.com
Intellia data spark debate about CRISPR drug’s potential - BioPharma Dive
Baird cuts Intellia stock target, neutral rating on gene editing concerns - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year LowShould You Sell? - MarketBeat
Intellia stock touches 52-week low at $16.86 amid market shifts - Investing.com
Intellia reports promising Phase 2 results for HAE treatment By Investing.com - Investing.com South Africa
Intellia stock slips after gene editing data (NTLA:NASDAQ) - Seeking Alpha
Intellia reports promising Phase 2 results for HAE treatment - Investing.com
CRISPR-Based Therapy for Hereditary Angioedema - nejm.org
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - StockTitan
Intellia Moves Into Phase III With NTLA-2002, But Concerns Remain - Citeline
2 Biotech Stocks Making Big Moves - Schaeffers Research
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 7.3%Here's Why - MarketBeat
(NTLA) Trading Signals - Stock Traders Daily
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '24 |
Sale |
22.93 |
405 |
9,287 |
71,470 |
| Verwiel Frank | Director |
Jun 17 '24 |
Sale |
25.00 |
1,505 |
37,625 |
17,948 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '24 |
Sale |
32.99 |
2,297 |
75,778 |
81,571 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '24 |
Sale |
32.99 |
605 |
19,959 |
71,470 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 08 '24 |
Sale |
28.87 |
2,275 |
65,682 |
43,927 |
| LEONARD JOHN M | President and CEO |
Jan 03 '24 |
Sale |
29.46 |
19,223 |
566,310 |
846,486 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '24 |
Sale |
29.46 |
5,843 |
172,135 |
54,372 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '24 |
Sale |
29.46 |
5,532 |
162,973 |
46,202 |
| Goddard Glenn | EVP, Chief Financial Officer |
Jan 03 '24 |
Sale |
29.46 |
5,365 |
158,053 |
40,585 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '24 |
Sale |
29.46 |
3,877 |
114,216 |
36,987 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):